Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations
Trends in Immunology · 2026-11 · 47 (11) · 966-978
DOI: 10.1016/j.it.2026.06.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2026-11. Verfasst von Gabriel Gomis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain. Hauptthemen laut MEDLINE: Cross-Priming, Immunoconjugates, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 89 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Inve…
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Centro de Investigación Biomédica En Red de Cáncer (CIBERONC), Madrid, Spain.
Zitieren
APA
Gomis, G., Berraondo, P., Herrero, C., Luri-Rey, C., & Melero, I. (2026). Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations. Trends in Immunology, 47(11), 966-978. https://doi.org/10.1016/j.it.2026.06.003
Vancouver
Gomis G, Berraondo P, Herrero C, Luri-Rey C, Melero I. Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations. Trends in Immunology. 2026;47(11):966-978. doi:10.1016/j.it.2026.06.003
BibTeX
@article{Gomis2026,
author = {Gomis, Gabriel and Berraondo, Pedro and Herrero, Claudia and Luri-Rey, Carlos and Melero, Ignacio},
title = {Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations},
journal = {Trends in Immunology},
year = {2026},
volume = {47},
number = {11},
pages = {966--978},
doi = {10.1016/j.it.2026.06.003}
}
EUVIMED